ClinicalTrials.gg
CompletedNCT01254643Updated Nov 28, 2018Results posted

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

A Phase 3 interventional study of V503 in Papillomavirus Infections, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 9 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
9 Years to 15 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.

Enrollment
29th of 31
100 · median 700
Started
2011
the only one that year
Phase 3
16 of 31
2 open now
Registered
2nd of 31
by date
Lead sponsor
15 of 31
Merck Sharp & Dohme LLC

Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 29th largest by enrollment, is the only one that started in 2011, is one of 16 in phase 3, and was the 2nd registered.

Papillomavirus Infections

580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 9 Years to 15 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, and immunogenicity of V503 in Japanese girls between the ages of 9 and 15 and will determine whether V503 induces an acceptable immune response to all human papillomavirus (HPV) strains contained in the vaccine. The success criterion for the primary analysis requires that point estimates for seroconversion rate be greater than 90% for all 9 HPV types.

03

Conditions studied

  • Papillomavirus Infections

Keywords

  • Papillomavirus vaccines
  • Uterine cervical cancer
  • Human Papilloma Virus infections
04

Who can participate

Ages eligible
9 Years to 15 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is in good physical health-
  • Participant's parent/legal guardian is able to read, understand, and complete the vaccine report card
  • Participant's parent/legal guardian agrees to provide a phone number for follow-up purposes
  • Participant is not sexually active and does not plan to become sexually active during the time from Day 1 to Month 7 of the study

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of severe allergic reaction that required medical intervention
  • Participant has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection
  • Participant is pregnant
  • Participant intends to donate blood during the time from Day 1 to Month 7 of the study
  • Participant is or has been diagnosed as having a congenital or acquired immunodeficiency, (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other condition.
  • Participant has had a splenectomy
  • Participant has received any of the following immunosuppressive therapies in the year prior to enrollment: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (Arava), tumor necrosis factor alpha (TNF-α) antagonists, monoclonal antibody therapies, antilymphocyte sera, or other therapy known to interfere with the immune response.
  • Participant has received any immune globulin product or blood-derived product in the three months prior to the Day 1 vaccination, or plans to receive any such product through Month 7 of the study
  • Participant has received any inactivated vaccines within 14 days of the Day 1 vaccination or any within 28 days of the Day 1 vaccination
  • Participant has received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial
  • Participant has had a fever (oral temperature ≥37.8°C) within 24 hours of the Day 1 vaccination
  • Participant has a history of a positive test for HPV or history of genital warts
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    All Enrolled

    9-valent human papillomavirus (9vHPV) L1 VLP vaccine (V503), 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6.

    Biological: V503

Interventions

  • BiologicalV503

    V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine

    Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using competitive luminex immunoassay (cLIA). The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.

    Time frame: 4 weeks post-vaccination 3 (Month 7)

  2. Percentage of Participants With an Injection-site Adverse Event (AE)

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.

    Time frame: up to 5 days after any vaccination

  3. Percentage of Participants With a Non-Injection Site (Systemic) AE

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.

    Time frame: up to 15 days after any vaccination

  4. Percentage of Participants With a Vaccine-related AE

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Adverse experience that is judged by the Investigator to be "definitely related," "probably related," or "possibly related" to the study drug is defined as a vaccine-related AE.

    Time frame: up to 15 days after any vaccination

Secondary outcomes

  1. Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine

    Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. Titers are reported in milli Merck Units/mL.

    Time frame: 4 weeks post-vaccination 3 (Month 7)

07

Results

Posted Dec 22, 2014

Participant flow

Participant flow — Overall Study
MilestoneAll Enrolled
Started100
Vaccination 1100
Vaccination 299
Vaccination 399
Completed99
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine

Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using competitive luminex immunoassay (cLIA). The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.

Time frame:
4 weeks post-vaccination 3 (Month 7)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine
Percentage of ParticipantsAll Enrolled
Anti-HPV 6 (n=97)100 (96.3 to 100)
Anti-HPV 11 (n=97)100 (96.3 to 100)
Anti-HPV 16 (n=99)100 (96.3 to 100)
Anti-HPV 18 (n=98)100 (96.3 to 100)
Anti-HPV 31 (n=97)100 (96.3 to 100)
Anti-HPV 33 (n=98)100 (96.3 to 100)
Anti-HPV 45 (n=99)100 (96.3 to 100)
Anti-HPV 52 (n=99)100 (96.3 to 100)
Anti-HPV 58 (n=95)100 (96.2 to 100)
PrimaryPercentage of Participants With an Injection-site Adverse Event (AE)

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.

Time frame:
up to 5 days after any vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With an Injection-site Adverse Event (AE)
Percentage of ParticipantsAll Enrolled
Percentage of Participants With an Injection-site Adverse Event (AE)95.0
PrimaryPercentage of Participants With a Non-Injection Site (Systemic) AE

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.

Time frame:
up to 15 days after any vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Non-Injection Site (Systemic) AE
Percentage of ParticipantsAll Enrolled
Percentage of Participants With a Non-Injection Site (Systemic) AE35.0
PrimaryPercentage of Participants With a Vaccine-related AE

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Adverse experience that is judged by the Investigator to be "definitely related," "probably related," or "possibly related" to the study drug is defined as a vaccine-related AE.

Time frame:
up to 15 days after any vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Vaccine-related AE
Percentage of ParticipantsAll Enrolled
Percentage of Participants With a Vaccine-related AE96.0
SecondaryGeometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine

Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. Titers are reported in milli Merck Units/mL.

Time frame:
4 weeks post-vaccination 3 (Month 7)
Reported as:
Geometric mean · milli Merck units/mL
Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine
milli Merck units/mLAll Enrolled
Anti-HPV 6 (n=97)1836.5 (1597.7 to 2111.0)
Anti-HPV 11 (n=97)1331.3 (1135.0 to 1561.4)
Anti-HPV 16 (n=99)6823.6 (5907.9 to 7881.2)
Anti-HPV 18 (n=98)2159.9 (1803.8 to 2586.3)
Anti-HPV 31 (n=97)2052.5 (1735.9 to 2426.8)
Anti-HPV 33 (n=98)994.8 (857.2 to 1154.4)
Anti-HPV 45 (n=99)811.0 (679.7 to 967.6)
Anti-HPV 52 (n=99)1069.1 (908.4 to 1258.4)
Anti-HPV 58 (n=95)1488.2 (1285.0 to 1723.4)

Adverse events

Collected over Up to 5 days after any vaccination (Non-serious injection site AEs); up to 15 days after any vaccination (Serious AEs and Non-serious non-injection site AEs) and up to 30 months (Any death and serious drug-related AEs). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Enrolled—0/100 (0%)96/100 (96%)
Most frequent other events
Most frequent other events
EventAll Enrolled
Injection site painGeneral disorders93/100
Injection site swellingGeneral disorders42/100
Injection site erythemaGeneral disorders33/100
NasopharyngitisInfections and infestations9/100
HeadacheNervous system disorders8/100
PyrexiaGeneral disorders6/100

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Enrolled
Mean11.7 ± 1.7
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled
Female100
Male0
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Iwata S, Murata S, Rong Han S, Wakana A, Sawata M, Tanaka Y. Safety and Immunogenicity of a 9-Valent Human Papillomavirus Vaccine Administered to 9- to 15-Year-Old Japanese Girls. Jpn J Infect Dis. 2017 Jul 24;70(4):368-373. doi: 10.7883/yoken.JJID.2016.299. Epub 2016 Dec 22. PubMed 28003597 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2011 to primary completion in Aug 2013, 30 months.

Results were first posted in Dec 2014, 1 year 4 months after primary completion.

Of 54 industry-sponsored phase 3 interventional studies under Papillomavirus Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 64. This study's 30 months is above that.

Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2010
First posted
Dec 6, 2010
StartActual
Jan 12, 2011
Primary completionActual
Aug 10, 2013
CompletionActual
Aug 10, 2013
Results first posted
Dec 22, 2014
Last update
Nov 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01254643
Responsible party
Sponsor
First posted
Dec 6, 2010
Start date
Jan 12, 2011
Primary completion
Aug 10, 2013
Completion
Aug 10, 2013
Results posted
Dec 22, 2014
Last update
Nov 28, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion